About
The proxy statement says Francis was CEO of Sandoz from 2014 to 2019 and a member of the Novartis executive team. Before that he spent 13 years at Biogen, where he held senior roles including leading its U.S. business. From 2021 to 2022 he was CEO of Purespring Therapeutics and of Forcefield Therapeutics. He holds a Bachelor of Arts in Economics from Manchester Metropolitan University. Other pharmaceutical company leaders on Whoo include Albert Bourla of Pfizer and Mike Doustdar of Novo Nordisk.
Whoo compiled this page from public sources: Teva 2026 proxy statement (SEC), Teva third-quarter 2026 results release (SEC), Teva Form 10-K (SEC). It is not affiliated with or endorsed by Richard Francis. Are you Richard Francis? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.
Want a page like this? Create yours from your résumé.
Experience
President, Chief Executive Officer and Director — Teva Pharmaceutical Industries
January 2023 – Present
Chief Executive Officer — Purespring Therapeutics and Forcefield Therapeutics
2021 – 2022
Chief Executive Officer — Sandoz
2014 – 2019
- Member of the Novartis executive team
- Held several senior roles, including leading the U.S. business
Senior Executive — Biogen
13 years